V

    Vor Biopharma Inc (VOR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $22.48
    -0.17 (-0.75%)

    Market Cap: $1.33B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(9/24)
    Avg Surprise
    +590.92%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.77
    Range$-0.95 - $-0.59
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    2
    30d
    EPS Estimate Drift
    90d ago$-1.22-58.8%
    60d ago$-0.85-11.3%
    30d ago$-0.77+0.0%
    7d ago$-0.77+0.0%
    Current$-0.77
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-4.28
    Range$-4.28 - $-4.28
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-4.28---
    Sep 26EST
    		-$-0.77---
    Jun 26
    Reported Aug 11
    		$-0.80$-0.69-15.94%Miss+99.7%
    Mar 26
    Reported May 13
    		$-0.73$-0.78+6.41%Beat+86.0%
    Dec 25
    Reported Mar 30
    		$307.53$-1.19+25921.16%Beat+69993.2%
    Sep 25
    Reported Nov 13
    		$-121.63$-4.10-2866.59%Miss-1420.4%
    Jun 25
    Reported Aug 12
    		$-251.20$-11.80-2028.81%Miss-2963.4%
    Mar 25
    Reported May 14
    		$-5.20$-4.16-25.00%Miss+42.2%
    Dec 24
    Reported Mar 20
    		$-0.44$-0.31-43.46%Miss-12.8%
    Sep 24
    Reported Nov 7
    		$-8.00$-0.40-1900.00%Miss+18.4%
    Jun 24
    Reported Aug 8
    		$-8.20$-8.29+1.09%Beat+8.9%
    Mar 24
    Reported May 9
    		$-9.00$-7.63-17.96%Miss-4.7%
    Dec 23
    Reported Mar 20
    		$-0.39$-0.50+22.00%Beat+25.0%
    Sep 23
    Reported Nov 7
    		$-9.80$-9.17-6.87%Miss+22.2%
    Jun 23
    Reported Aug 10
    		$-9.00$-8.46-6.38%Miss+22.4%
    Mar 23
    Reported May 11
    		$-8.60$-7.77-10.68%Miss+29.5%
    Dec 22
    Reported Mar 23
    		$-0.52$-0.60+13.33%Beat-8.3%
    Sep 22
    Reported Nov 10
    		$-12.60$-11.89-5.97%Miss-26.0%
    Jun 22
    Reported Aug 11
    		$-11.60$-13.00+10.77%Beat-16.0%
    Mar 22
    Reported May 12
    		$-12.20$-10.29-18.56%Miss+9.0%
    Dec 21
    Reported Mar 14
    		$-0.48$-0.57+15.79%Beat+99.8%
    Sep 21
    Reported Nov 10
    		$-10.00$-11.50+13.04%Beat-37.7%
    Jun 21
    Reported Aug 9
    		$-10.00$-9.27-7.87%Miss-114.0%
    Mar 21
    Reported May 6
    		$-13.40$-15.20+11.84%Beat-224.0%
    Dec 20
    Reported Mar 25
    		$-217.49$-4.40-4842.95%Miss-5159.2%
    Sep 20
    Reported Dec 18
    		$-7.26$-5.33-36.21%Miss-177.1%
    Jun 20
    Reported Sep 30
    		$-4.67$0.00N/AMiss-251.9%
    Mar 20
    Reported Jun 30
    		$-4.14$0.00N/AMiss-211.4%
    Dec 19
    Reported Mar 30
    		$-4.14$0.00N/AMiss-
    Jun 19
    Reported Sep 30
    		$-2.62$0.00N/AMiss-
    Mar 19
    Reported Jun 29
    		$-1.33$0.00N/AMiss-
    Dec 18
    Reported Mar 30
    		$-1.33$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio0.12EV/EBITDA-3.09x
    Price/FCF-8.67xFCF Yield-11.53%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-125.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio19.15xQuick Ratio19.15x
    Trading Statistics
    Beta1.72Avg Volume751.22K
    52-Week High$49.9552-Week Low$6.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$23.23
    SMA 20$23.14
    SMA 50$20.44
    SMA 200$15.35
    EMA 10$23.06
    EMA 20$22.64
    EMA 50$20.72
    EMA 200$18.50

    MACD

    Line: 0.77Signal: 1.03Hist: -0.26

    ADX

    ADX: 27.8+DI: 23.0-DI: 19.8

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down4.0
    PSAR$24.30

    Bollinger Bands

    Upper Band$24.21
    Lower Band$22.08
    %B Position922%(Upper)
    Band Width0.19

    RSI (14-Day)

    Neutral
    52.1

    Momentum Oscillators

    Stoch %K40.7
    Stoch %D55.6
    Williams %R-73.8
    ROC (10d)-2.3%
    Momentum-0.53
    CCI (20d)-91.4
    MFI (14d)50.1

    Volatility Measures

    ATR (14d)$1.19(5.3%)
    StdDev (20d)0.53
    Hist Vol47.7%(High)

    Volume Flow

    VWAP$22.51
    OBV812.5M
    AD Line210.5B
    CMF (20d)0.072

    Volume Metrics

    Avg Vol (20d)746.2K
    Vol Ratio1.1x
    VWMA (20d)$23.16

    Pivot Points

    R3$24.08
    R2$23.68
    R1$23.17
    Pivot Point$22.77
    S1$22.26
    S2$21.86
    S3$21.35

    Advanced Oscillators

    TSI19.13
    Ultimate Osc51.1
    KST153.99

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$3.69M$0$0$0$12.23M$0
    Cost of Revenue$0$0$23,000$0$0$0$865,000$0$0$0$892,000$0
    Gross Profit$0$0$-23,000$0$0$0$-865,000$0$0$0$-892,000$0
    Operating Expenses$47.85M$35.16M$35.96M$28.11M$274.28M$33.29M$31.31M$28.51M$29.04M$32.33M$28.12M$35.32M
    R&D$25.92M$17.59M$19.19M$14.14M$261.50M$26.70M$25.35M$21.82M$21.82M$24.32M$20.90M$27.61M
    SG&A$21.93M$17.57M$16.77M$13.96M$12.79M$6.59M$5.96M$6.70M$7.21M$8.00M$7.23M$7.71M
    Operating Income$-47,853,000$-35,160,000$-35,960,000$-28,107,000$-274,284,000$-33,291,000$-31,311,000$-28,513,000$-29,035,000$-32,326,000$-28,124,000$-35,316,000
    Interest Income$4.34M$3.94M$2.79M$1.73M$537,000$805,000$599,000$954,000$1.20M$1.52M$1.86M$2.13M
    Interest Expense$14.96M$184.43M$0$784.58M$1.30B$0$0$0$0$0$0$0
    Income Before Tax$-62,810,000$-219,585,000$1.72B$-812,684,000$-1,573,669,000$-32,486,000$-30,712,000$-27,559,000$-27,839,000$-30,804,000$-26,261,000$-33,190,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-62,810,000$-219,585,000$1.72B$-812,684,000$-1,573,669,000$-32,486,000$-30,712,000$-27,559,000$-27,839,000$-30,804,000$-26,261,000$-33,190,000
    EBITDA$-67,542,000$-223,980,000$-35,971,000$-814,424,000$-1,572,180,000$-32,477,000$-30,458,000$-27,673,000$-28,495,000$-32,180,000$-28,218,000$-35,650,000
    EBIT$-67,153,000$-223,520,000$-35,960,000$-814,415,000$-1,574,206,000$-33,291,000$-31,311,000$-28,513,000$-29,035,000$-32,326,000$-28,124,000$-35,316,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VOR

    News

    Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

    Vor Biopharma (VOR) has a consensus price target indicating a potential upside of 124.6%, with an average target of $35.71 from seven analysts. While price targets can be misleading, a strong agreement among analysts on earnings revisions, along with a Zacks Rank #2 (Buy), suggests a legitimate reason for optimism regarding the stock's near-term potential. Investors are advised to use price targets as a starting point for further research rather than the sole basis for investment decisions.

    qz.com•8/26/26•
    Somewhat-Bullish

    How Investors Are Reacting To Vor Biopharma (VOR) Sharply Narrowed Losses And Earnings Profile Shift

    Vor Biopharma recently reported a sharp reduction in net losses for Q2 2026, with loss per share significantly narrowing compared to the previous year. Despite this improvement, the company still faces fundamental challenges, including no revenue, declining

    Simply Wall Street•8/18/26•
    Neutral

    How Investors Are Reacting To Vor Biopharma (VOR) Sharply Narrowed Losses And Earnings Profile Shift

    Vor Biopharma recently reported a significant narrowing of losses in Q2 2026, with net loss at US$62.81 million and basic loss per share at US$1.16, indicating an improved cost and earnings profile. Despite this, the company still lacks revenue, and its investment narrative heavily relies on successful Phase 3 outcomes and future approvals outside Greater China, presenting ongoing clinical, financing, and governance risks. The wide range of fair value estimates from the Simply Wall St Community highlights the diverse investor opinions and the importance of weighing clinical milestones against dilution risks.

    Simply Wall Street•8/17/26•
    Somewhat-Bullish

    Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

    Wall Street Zen has upgraded Vor Biopharma (NASDAQ:VOR) from a "sell" to a "hold" rating. Despite this, the overall analyst consensus for Vor Biopharma remains a "Moderate Buy" with an average price target of $43.38, though the company's stock trades significantly below its 52-week high. Vor Biopharma recently missed its quarterly earnings estimates, reporting a loss of $0.80 per share, and analysts anticipate the company will remain unprofitable for the current fiscal year.

    MarketBeat•8/15/26•
    Neutral

    Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership

    Frazier Life Sciences-affiliated funds have filed an amended Schedule 13G indicating beneficial ownership of less than 5% of Vor Biopharma Inc. common stock. Frazier Life Sciences Public Fund, L.P. holds 4.2% of the class, while Frazier Life Sciences XII, L.P. holds 0.5%, and Frazier Life Sciences XI, L.P. holds 0.0%, all based on 54,185,877 shares outstanding as of May 7, 2026. The filing specifies that these entities have shared voting and dispositive power, and no individual committee members are attributed beneficial ownership.

    Stock Titan•8/15/26•
    Neutral

    Frequently Asked Questions About VOR

    Does VOR pay dividends?
    Vor Biopharma Inc (VOR) does not currently pay a regular dividend.
    What is VOR's P/E ratio?
    Vor Biopharma Inc has a price-to-earnings (P/E) ratio of 0.12.
    What is VOR's market cap?
    Vor Biopharma Inc (VOR) has a market capitalization of $1.33B with a current stock price of $22.48.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In